Fresenius Medical Care AG - FMS STOCK NEWS

Fresenius Kidney Care has launched a pioneering home dialysis training program at its Indianapolis Shadeland Station, aimed at facilitating a smooth transition for patients moving from in-center treatment to home therapy. The program prioritizes community building among patients and offers tailored training with dedicated care teams. Wendy Taylor, Home Therapy Clinic Manager, highlighted the program’s efficiency in getting both hemodialysis and peritoneal dialysis patients ready for home therapy. Since its inception in January 2023, two patients have successfully transitioned to home dialysis, enhancing their treatment autonomy and quality of life.

Fresenius Kidney Care has announced a $150,000 donation to the Food Is Medicine Coalition (FIMC) to enhance access to medically tailored meals for patients with chronic kidney disease (CKD) across the U.S. This initiative, part of their long-term partnership, aims to fund the FIMC Accelerator Program and establish an accreditation program to maintain quality standards for meal providers. March, recognized as National Kidney Month, highlights the importance of education and nutrition in managing CKD, which affects about 37 million American adults. By providing tailored meal plans, Fresenius hopes to improve health outcomes and quality of life for those facing severe illnesses.

Fresenius Kidney Care has committed $275,000 to the Boys & Girls Clubs of America to enhance kidney health education and advocacy among youth. This donation is part of an ongoing partnership aimed at promoting healthy living and active learning. The initiative includes the Kidney Kid Program, which engages volunteers to educate children on kidney health through fun activities and challenges. With the support of Fresenius, BGCA leaders will also advocate for youth issues during National Advocacy Days in Washington, D.C. This effort is aligned with National Kidney Month, emphasizing the importance of early detection of kidney disease, affecting 1 in 7 American adults.

Fresenius Medical Care (OTC-PINK:FSMEM) has committed to the Zero Health Gaps Pledge at the World Economic Forum in Davos, Switzerland, joining 36 global companies in addressing health inequities. The pledge aligns with UN Sustainable Development Goals, emphasizing equitable healthcare access as a fundamental human right. The company aims to utilize its Health Equity Dashboard to tailor interventions based on demographic data, improving outcomes for dialysis patients worldwide. CEO Helen Giza highlighted the company’s dedication to addressing these challenges and ensuring sustainability in their practices.

Fresenius Medical Care North America (FMCNA) has received a grant exceeding $130,000 from the Mississippi Department of Health to enhance kidney disease education through virtual reality (VR) technologies. This initiative targets rural Mississippi patients, offering immersive experiences that illustrate the benefits of home dialysis. The partnership with IKONA Health aims to improve patient understanding and outcomes, with the project also being implemented in other states. As chronic kidney disease affects approximately 15% of US adults, this initiative seeks to empower patients by providing better access to treatment education.

Fresenius Medical Care has partnered with the National Kidney Foundation Malaysia (NKF) to promote kidney health among children. The initiative, part of the global The Kidney Kid program, aims to educate children and families about chronic kidney disease prevention. The program, which began in 2017, has engaged over 60,000 children across Asia Pacific. The partnership addresses the rising number of kidney failure cases in Malaysia, where over 8,000 new diagnoses occur annually. Activities will commence in October, targeting schools and community engagement.

Fresenius Medical Care and CytoSorbents have enhanced their partnership through a multi-stage collaboration aimed at innovating and expanding sales opportunities in critical care. This three-year agreement will see Fresenius Medical Care actively market CytoSorb as a primary blood purification therapy for critical conditions, excluding the U.S. The collaboration promises to leverage various marketing strategies to increase the visibility of CytoSorb while ensuring its compatibility with Fresenius Medical Care's existing platforms. This initiative is expected to drive growth and enhance patient care.